{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:24:02Z","timestamp":1787027042562,"version":"build-2736575974"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Over-the-counter cannabidiol (CBD) products are showing substantial growth in marked share in recent years. However, the knowledge about health effects of these products is currently weak. In an explorative, retrospective online survey, the reasons for consumption, possible health-promoting or therapeutic effects, and adverse effects among CBD consumers in Germany were investigated. The anonymous questionnaire was accessible from 21 February 2023 to 20 June 2023. Participants (n = 208) were recruited mainly via social internet platforms. The study data was collected and managed using SoSci-Survey\n                    <jats:sup>\u00ae<\/jats:sup>\n                    . The study group was predominantly female (66%), between 41\u201360\u00a0years old (46%), and most of them were chronic CBD consumers (&amp;gt;3 months, at least daily). The principal mode of CBD use was oil (36%) with a CBD concentration between 10%\u201320%. Overall, the CBD products were mostly reported to have a positive effect on health. One of the main reasons for use was for improving physical and mental capacities. Here, the effect of CBD was rated effective for helping the general state of health (89%), and for the wellbeing (89%). In 79% of cases, the CBD product was rated as effective in alleviating disease symptoms. Improvements were reported especially in relief from pain (general, chronic, muscle and joint pain), or psychological symptoms (sleep disorders, nervousness, anxiety). Reported adverse effects were mainly dry mouth and sleepiness, but for 69% of the participants, no adverse effects were reported. A strong belief in the efficacy of dietary supplements, natural remedies, and CBD products among users suggests that expectation and placebo effects may have played a relevant role in the reported outcomes. This should be considered when interpreting the results and underlines the need for further controlled studies to differentiate pharmacological effects from psychological influences.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2025.1571025","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:24:50Z","timestamp":1747790690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Over the counter CBD products in Germany: an exploratory survey about consumption patterns and health related effects"],"prefix":"10.3389","volume":"16","author":[{"given":"Anaelle","family":"Weissgerber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Hermanns-Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","article-title":"Project code: FS121029","year":"2023","DOI":"10.46756\/sci.fsa.zcg392"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cts.13425","article-title":"The safety and efficacy of low oral doses of cannabidiol: an evaluation of the evidence","volume":"16","author":"Arnold","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1684\/epd.2020.1141","article-title":"Epilepsy and cannabidiol: a guide to treatment","volume":"22","author":"Arzimanoglou","year":"2020","journal-title":"Epileptic Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antiox9010021","article-title":"Antioxidative and anti-inflammatory properties of cannabidiol","volume":"9","author":"Atalay","year":"2019","journal-title":"Antioxidants (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/nm.2435","article-title":"Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors","volume":"17","author":"Benedetti","year":"2011","journal-title":"Nat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-pharmtox-052120-104536","article-title":"Thirty years of neuroscientific investigation of placebo and nocebo: the interesting, the good, and the bad","volume":"62","author":"Benedetti","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B18","unstructured":"Fragen und Antworten zu den gesundheitlichen Risiken von hanfhaltigen Lebensmitteln und Futtermitteln\n          \n          \n            \n              Bundesinstitut f\u00fcr Risikobewertung\n              B.\n            \n          \n          \n          2022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.bmc.2015.01.059","article-title":"Cannabidiol (CBD) and its analogs: a review of their effects on inflammation","volume":"23","author":"Burstein","year":"2015","journal-title":"Bioorg Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1080\/08998280.2020.1775437","article-title":"Cannabidiol primer for healthcare professionals","volume":"33","author":"Cather","year":"2020","journal-title":"Proc. Bayl Univ. Med. Cent."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","article-title":"Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Chesney","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/can.2018.0006","article-title":"A cross-sectional study of cannabidiol users","volume":"3","author":"Corroon","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.31887\/DCNS.2020.22.3\/mcrocq","article-title":"History of cannabis and the endocannabinoid system","volume":"22","author":"Crocq","year":"2020","journal-title":"Dialogues Clin. Neurosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s43856-022-00202-8","article-title":"Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial","volume":"2","author":"Dahlgren","year":"2022","journal-title":"Commun. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/nu17030489","article-title":"Cannabidiol in foods and food supplements: evaluation of health risks and health claims","volume":"17","author":"Engeli","year":"2025","journal-title":"Nutrients"},{"key":"B16","unstructured":"(bundesgerichtshof), decision of June 23, 2022 \u2013 5 StR 490\/21\n          \n          \n          2022"},{"key":"B17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s42238-021-00102-z","article-title":"Reasons for using cannabidiol: a cross-sectional study of French cannabidiol users","volume":"3","author":"Fortin","year":"2021","journal-title":"J. Cannabis Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S2215-0366(16)30307-8","article-title":"Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies","volume":"3","author":"Furukawa","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1186\/s12889-023-17142-0","article-title":"Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021","volume":"23","author":"Geppert","year":"2023","journal-title":"BMC Public Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000489291","article-title":"The intricate influence of the placebo effect on medical cannabis and cannabinoids","volume":"1","author":"Gertsch","year":"2018","journal-title":"Med. Cannabis Cannabinoids"},{"key":"B22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3238\/arztebl.2012.0459","article-title":"Nocebo phenomena in medicine: their relevance in everyday clinical practice","volume":"109","author":"H\u00e4user","year":"2012","journal-title":"Dtsch. Arztebl Int."},{"key":"B23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/biology11060817","article-title":"Mechanisms of cannabidiol (CBD) in cancer treatment: a review","volume":"11","author":"Heider","year":"2022","journal-title":"Biol. (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1423","DOI":"10.1089\/can.2023.0117","article-title":"Cannabidiol oil ingested as sublingual drops or within gelatin capsules shows similar pharmacokinetic profiles in healthy males","volume":"9","author":"Johnson","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"B26","volume-title":"Heilen Mit CBD: Das Wissenschaftlich Fundierte Handbuch zur Medizinischen Anwendung von Cannabidiol","author":"Leinow","year":"2019"},{"key":"B27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/can.2019.0078","article-title":"An analysis of over-the-counter cannabidiol products in the United Kingdom","volume":"7","author":"Liebling","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"key":"B28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00003-024-01513-9","article-title":"Comprehensive analysis of 19 cannabinoids in commercial CBD oils: Concentrations, profiles, and safety implications","volume":"19","author":"Lindekamp","year":"2024","journal-title":"J. Consum. Prot. Food Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/biomedicines11020469","article-title":"Endocannabinoid degradation enzyme inhibitors as potential antipsychotics: a medicinal chemistry perspective","volume":"11","author":"Mangiatordi","year":"2023","journal-title":"Biomedicines"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102935","DOI":"10.1016\/j.drugpo.2020.102935","article-title":"Access to cannabidiol without a prescription: a cross-country comparison and analysis","volume":"85","author":"McGregor","year":"2020","journal-title":"Int. J. Drug Policy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","article-title":"Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems","volume":"3","author":"Moltke","year":"2021","journal-title":"J. Cannabis Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e300630","DOI":"10.1136\/bmjment-2022-300630","article-title":"Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan: a three-level meta-analysis","volume":"26","author":"Motta","year":"2023","journal-title":"BMJ Ment. Health"},{"key":"B44","unstructured":"Novel food status catalogue Food Safety\n          \n          \n          2025"},{"key":"B34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3389\/fneur.2018.00759","article-title":"Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis","volume":"9","author":"Pamplona","year":"2018","journal-title":"Front. Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1097\/j.pain.0000000000000540","article-title":"Relieving patients' pain with expectation interventions: a meta-analysis","volume":"157","author":"Peerdeman","year":"2016","journal-title":"Pain"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3928\/00989134-20210610-02","article-title":"Cannabidiol (CBD) use by older adults for acute and chronic pain","volume":"47","author":"Porter","year":"2021","journal-title":"J. Gerontol. Nurs."},{"key":"B37","unstructured":"Fachinformation epidyolex 100 mg\/ml l\u00f6sung zum einnehmen\n          \n          \n          2024"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.23.02.0031","article-title":"A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals","volume":"84","author":"Schwark","year":"2023","journal-title":"Am. J. Vet. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7812\/TPP\/18-041","article-title":"Cannabidiol in anxiety and sleep: a large case series","volume":"23","author":"Shannon","year":"2019","journal-title":"Perm. J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fphar.2017.00020","article-title":"In vivo evidence for therapeutic properties of cannabidiol (CBD) for alzheimer's disease","volume":"8","author":"Watt","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1177\/02698811231219060","article-title":"The impact of cannabidiol placebo on responses to an acute stressor: a replication and proof of concept study","volume":"38","author":"Zhekova","year":"2024","journal-title":"J. Psychopharmacol."},{"key":"B43","article-title":"Cannabidiol (CBD): analyse de situation","volume-title":"Lausanne: addiction suisse","author":"Zobel","year":"2017"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1571025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:24:53Z","timestamp":1747790693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1571025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1571025"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1571025","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1571025"}}